Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $22.5 million.

  • Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) rose 338.72% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year increase of 338.72%. This contributed to the annual value of $21.3 million for FY2024, which is 1383.36% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) is $22.5 million, which was up 338.72% from $22.2 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $22.5 million during Q3 2025, with a 5-year trough of $15.8 million in Q1 2021.
  • For the 5-year period, Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $18.9 million, with its median value being $18.3 million (2023).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 278.62% in 2022, and later soared by 1769.56% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $16.5 million in 2021, then grew by 3.64% to $17.1 million in 2022, then rose by 9.05% to $18.7 million in 2023, then rose by 13.83% to $21.3 million in 2024, then grew by 5.69% to $22.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $22.5 million in Q3 2025, compared to $22.2 million in Q2 2025 and $22.1 million in Q1 2025.